TY  - JOUR
AU  - Trieu, Phillip
AU  - Fetzer, Dominique
AU  - McLeod, Briana
AU  - Schweickert, Kathryn
AU  - Gutstein, Lauren
AU  - Egleston, Brian
AU  - Domchek, Susan
AU  - Fleisher, Linda
AU  - Wagner, Lynne
AU  - Wen, Kuang-Yi
AU  - Cacioppo, Cara
AU  - Ebrahimzadeh, Jessica E
AU  - Falcone, Dana
AU  - Langer, Claire
AU  - Wood, Elisabeth
AU  - Karpink, Kelsey
AU  - Posen, Shelby
AU  - Selmani, Enida
AU  - Bradbury, Angela R
PY  - 2025
DA  - 2025/5/14
TI  - Developing the MyCancerGene Digital Health Portal to Improve Patients’ Understanding of Germline Cancer Genetic Test Results: Development, User, and Usability Testing Study
JO  - JMIR Form Res
SP  - e56282
VL  - 9
KW  - genetic health portal
KW  - digital intervention development
KW  - health portal
KW  - usability
KW  - digital health
KW  - germline cancer
KW  - multigene panels
KW  - clinical practice
KW  - likelihood
KW  - effectiveness
KW  - medical history
KW  - genetic medicine
KW  - risk information
KW  - digital tool
KW  - intervention
KW  - longitudinal care
KW  - patient-centered content
KW  - electronic information
AB  - Background: The use of multigene panels has significantly increased the likelihood that genetic testing will leave patients with uncertainties regarding test interpretation, implications, and recommendations, which will change over time. Effective longitudinal care models are needed to provide patients with updated information and to obtain patient and family history updates. Objective: To bridge this gap, we aimed to develop a patient- and genetic provider–informed digital genetic health portal (GHP), MyCancerGene, to improve longitudinal patient understanding of and responses to genetic testing. Methods: We used a 5-step process to develop MyCancerGene. To better understand their interest in and willingness to use a digital GHP, we surveyed 307 patients who completed genetic testing (step 1). We completed qualitative interviews with 10 patients and a focus group with 17 genetic providers to inform the content and function of MyCancerGene (step 2). Next, we developed initial intervention content (step 3) and completed user testing of intervention content with 25 providers and 28 patients (step 4). After developing the prototype intervention, we completed usability testing with 8 patients for their feedback on the final content, functions, and ease of use (step 5). Results: In surveys conducted in step 1, 90% of patients with positive results reported interest in a digital GHP, and over 75% of participants with variants of uncertain significance or uninformative negative results reported similar interest. The most frequently reported advantages among patients were increasing accessibility, convenience, and efficiency (103/224, 46%); keeping genetic information organized (54/224, 24.1%); and increasing or maintaining patient understanding of the information (38/224, 17%). In qualitative interviews (step 2), both patients and genetic providers endorsed the benefit of the tool for updating personal and family history and for providers to share new risk information, test interpretation, or other medical changes. Patient and provider input informed eight key components of the tool: (1) Landing Page, (2) Summary of Care page, (3) My Genetic Test Results page, (4) My Family History page, (5) Provide an Update page, (6) Review an Update page, (7) Resources page, and (8) the Screenings Tracker. They also recommended key functions, including the ability to download and print materials and the inclusion of reminders and engagement functions. Potential challenges identified by patients included privacy and security concerns (67/206, 32.5%) and the potential for electronic information to generate distress (20/206, 9.7%). While patients were comfortable with updates (ie, even variant reclassification upgrades or clinically significant results), 44% (11/25) of genetic providers were uncomfortable sharing variant reclassification upgrades through MyCancerGene. Conclusions: MyCancerGene, a patient-centered digital GHP, was developed with extensive patient and genetic provider feedback and designed to enhance longitudinal patient understanding of and affective and behavioral responses to genetic testing, particularly in the era of evolving evidence and risk information. 
SN  - 2561-326X
UR  - https://formative.jmir.org/2025/1/e56282
UR  - https://doi.org/10.2196/56282
DO  - 10.2196/56282
ID  - info:doi/10.2196/56282
ER  -